Feb. 16, 2024, is a landmark date in the history of immuno-oncology.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
President-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to the post of secretary of the Department of Health and Human Services, placing the vaccine skeptic in charge of a vast empire of research, engineering, regulatory, and health care agencies.
NCI renewed the Comprehensive Cancer Center designation to the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, awarding it a five-year, $14.2 million grant.
Melissa L. Fishel was named the Myles Brand Scholar in Cancer Research by Indiana University Melvin and Bren Simon Comprehensive Cancer Center. Fishel is a tumor cell biologist working toward new targets and treatments for pancreatic cancer.
In preclinical work recently published in Nature Communications, Fred Hutchinson Cancer Center scientists used a genetic “chain reaction” to transform herpes simplex virus DNA during an HSV infection.
Wugen Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, announced it will initiate a phase II study in the first quarter of 2025 for the company’s potential first-in-class, investigational, anti-CD7 CAR T-cell therapy, WU-CART-007, in patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
